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Body composition in COPD; stepping back or
moving forward?The past two decades epidemiological and clinical inter-
vention studies have consistently shown that muscle wasting
is an important therapeutic target to compress COPD
morbidity. Various body composition methods are available
to estimate the size of whole body muscle mass. Like other
COPD assessment tools, expensive, invasive laboratory tests
are generally more accurate than field tests. Evaluation of
body composition methods is hampered by absence of a true
gold standard except for ‘‘carcass analysis’’. New methods
are therefore compared with reference methods that have
proven to be highly accurate and precise for assessment of
specific body compartments such as fat mass (hydrostatic
weighing), total body water (deuterium dilution) and lean
body mass (total body potassium by whole body gamma
counting). In this journal Rutten et al. present a critical view
on diagnosing muscle wasting by bioelectrical impedance
analysis (BIA) and appear to suggest that it is too early to
implement body composition in clinical practice due to
absence of appropriate reference values for fat-free mass
(FFM). Is it indeed time to step back or should we move
forward and even accelerate?
Stepping back
In 1985 Lukaski et al.1 introduced bioelectrical impedance
analysis as promising body composition method for clinical
use since it is non-invasive, takes only a few minutes and
requires no active collaboration of the patient. The analyzer
is portable and relatively inexpensive. Concern was raised
however about the validity of the method in patho physio-
logical states including COPD. In 1991 we reported the first
validation study of BIA in clinically stable patients with COPD
using deuterium dilution as reference method.2 This is
a logical reference since theprinciple of BIA is basedupon the
conductance through body fluids of an electrical current and
theoretically total body water is linearly related to height2/
body resistance or height2/body impedance1 assuming that
the Capacitance (Xc) is small relative to resistance. There-
after we performed several other methodological studies0954-6111/$ - see front matter ª 2009 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2009.09.010specifically focusing on the potential influence of shifts in
body water compartments on validity of BIA in COPD3 and in
other chronic wasting diseases including cancer4 and chronic
heart failure.5 As was also concluded by the ESPEN working
group on bioelectrical impedance analysis in 2004,6 our
studies collectively suggest that BIA works well in healthy
subjects and in patients with stable water and electrolytes
balance with a validated BIA equation that is appropriate
with regard to age, sex and race. While initially developed as
part of the validation studies, there is yet no clear rationale
for applying disease specific equations in clinically stable
chronic wasting conditions including COPD. This facilitates
comparative research and development of normal values for
nutritional assessment. BIA is however not suitable in
patients with extremely low FFMI (due to shrinkage of body
cell mass3) or patients with extra cellular water expansion3,6
irrespective of the underlying disease. In my opinion this
short coming will not be improved by further BIA algorithms.
In this journal Rutten et al.7 nevertheless step back and
present a new COPD specific BIA prediction equation. The
prediction equation was derived from a large sample of COPD
patients. Methodological limitations of the study however
preclude added value of this new disease specific formula. To
develop a BIA prediction model, measurements of test and
reference method should be performed exactly at the same
moment, under the same circumstances8 and not as indicated
in the paper ‘within two days’. While described as disease
specific, we should bear in mind that this as well as previous
COPD- prediction equations were derived from a selected
group of Caucasian patients with severe COPD eligible for
rehabilitation that does not cover the complete COPD spec-
trum. Most important and in contrast to earlier validation
studies, the present study used dual energy X-ray absorpti-
ometry (DEXA) as reference method. Although DEXA is an
expensive laboratory test and often only available in a hospital
setting, it is ignored that this technique was developed for
assessment of bonemineral density and that estimates for fat-
free mass and fat mass by DEXA are also derived from
prediction equations using under waterweighing as reference..
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composition method. Rutten et al. also addressed the issue of
cut off values to define normality of FFM. The relatively wide
age range of their study population allowed comparison
between 10 y-strata ranging from 40 to 80 years. Ageing
resulted, as expected, in a decline in FFM which remarkably
appeared to bemost pronounced for the male sub-group. This
observation calls for longitudinal analyses to investigate if, in
the absence of apparent weight loss, the age related decline
of FFM (often referred to as sarcopenia) in COPD is accelerated
or similar to healthy age matched subjects. Body composition
assessment is not only of interest for COPD to assess muscle
mass as important determinant of physical functioning but also
to assess the proportion and localization of fat mass as
potential determinant of the increased cardiovascular disease
risk. From that perspective it would have been interesting if
Rutten et al. had used the large sample size of their study
population and the DEXA method to compare the presented
pattern of age related FFM decline with the pattern of fat
mass, fat distribution and bone mass.
Moving forward
While field tests such as BIA and anthropometry have been
extremely useful in large epidemiological cohort studies to
identify ‘hidden muscle wasting’ in COPD and consistently
showed the prognostic value of low muscle mass in COPD,
current research and clinical care demand both a diagnostic
screening tool as well as accurate methods to measure effi-
cacy of intervention strategies on specific body compart-
ments. For broad diagnostic screening I would propose to
focus on application of two complimentary field tests (i.e
anthropometry and BIA) with rigid application of standard-
ized operation procedures and a rational choice for a suitable
prediction formula. This choicemay very well differ between
centres or countries as is the case for other clinical assess-
ment tools. The clear age dependency of body composition
calls for application of age-adjusted percentiles to tailor
clinical intervention strategies. So farwe can fairly state that
FFM-index values<10 percentile clearly reflect a high risk for
physical disability as proposed by Janssen et al.9 A broadening
of research focus in COPD from cachexia to sarcopenia with
a yet insufficiently known risk profile10 could provide a ratio-
nale to broaden the cut off value to< 25 percentile. Further
methodological research is needed to assess accuracy and
precision of methods in COPD that specifically focus on lower
limb muscle mass such as PET scan, MRI and ultrasound.
Unfortunately there is yet no clinical method available that
can accurately assess body composition in abnormal hydra-
tion states. The BIA derived phase anglemight qualify since it
reflects the relative contributions of fluid (resistance) and
cellular membranes (capacitance) of the human body.11 In
other chronic wasting conditions including advanced lung
cancer12 a low phase angle has been associated with poor
prognosis and is proposed as screening tool for decreased cell
integrity or even cell death. Evaluation of therapeutic inter-
ventions at an individual level is, even in normal hydrated
subjects, still hampered by poor accuracy of individual
methods to detect subtile changes in body composition. For
researchpurposes,accuracycanbe substantially improvedby
application of a 3 or 4 compartment model that incorporatesmeasurements of total body water (deuterium dilution or
BIA), total bone mineral content (DEXA) and body density
(hydrostatic weighing or air displacement plethysmography)
since this approach requires fewer assumptions than each of
the individual methods.13 From a clinical management and
patient perspective a 2 compartmentmodel will suffice since
body composition is never the only outcome parameter of
therapeutic interventions that target fat-free mass.References
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